Gdansk

• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 Diffuse Large B-Cell Lymphoma (DLBCL)
• A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting
  2023-506327-29-00 5 2025-05-14 Non-Small Cell Lung Cancer
• A Study of Duvelisib Versus the Anti-cancer Drugs Gemcitabine or Bendamustine in Patients With T Cell lymphoma (a type of blood cancer), whi … Recruiting
  2024-516605-23-00 5 2025-05-12 relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 Advanced or Metastatic Non-Squamous NSCLC
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido … Recruiting
  2024-515279-37-00 5 2025-04-17 Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
• A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting
  2024-511495-32-00 5 2025-04-16 Chronic Phase Chronic Myeloid Leukemia
• A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease Recruiting
  2024-516363-92-00 5 2025-04-08 Psychosis Associated with Alzheimer’s Disease
• A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacod … Recruiting
  2024-517957-29-00 4 2025-04-02 Mild Cognitive Impairment (MCI)
• A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t … Recruiting
  2024-512496-12-00 5 2025-04-01 Moderate to Severe Plaque Psoriasis
• A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi … Recruiting
  2023-509070-36-00 5 2025-03-18 Major Depressive Disorder with Insomnia Symptoms
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• A clinical study of MK-0472 in people with solid tumors (MK-0472-001) Recruiting
  2024-516006-32-00 1 2025-03-11 Malignant Neoplasm - Solid Tumors
• Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting
  2023-506288-33-00 9 2025-03-03 Metastatic castration resistant prostate cancer (mCRPC)
• KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di … Recruiting
  2023-509234-19-00 4 2025-03-03 Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• Application of the autologous CAR T cells (Tarcidomgen Kimleucel) in the treatment of refractory and relapsed CD19+ B cell neoplasms Recruiting
  2025-520653-37-00 1 2025-01-30 Application of the autologous CAR T cells (Tarcidomgen Kimleucel) in t
• Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Recruiting
  2024-512264-66-00 7 2025-01-29 Solid Tumors
• A multicenter, randomized, blinded, placebo controlled, phase II study to evaluate the safety and efficacy of cell therapy based with artifi … Recruiting
  2023-505226-33-00 4 2025-01-28 Presymptomatic diabetes type 1 (stage 1)
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizum … Recruiting
  2023-503675-24-00 5 2025-01-17 Triple-negative Breast Cancer
• Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and pla … Recruiting
  2023-510338-10-00 5 2025-01-15 Recurrent herpes labialis (RHL)

Showing 241–264 of 854 trials